Sign In
Buy DARE
$2.05
-0.0900 (-4.21%)
At Close: Jun 03, 2026
4 Penny Stocks To Buy For Under $4 Right Now
05:22pm, Wednesday, 19'th Jan 2022 PennyStocks
Cheap penny stocks to watch right now.
The post 4 Penny Stocks To Buy For Under $4 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
4 Penny Stocks To Buy For Under $4 Right Now
12:22pm, Wednesday, 19'th Jan 2022
Cheap penny stocks to watch right now. The post 4 Penny Stocks To Buy For Under $4 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
These Penny Stocks Climbed Today, Here’s Why
05:37pm, Thursday, 16'th Dec 2021 PennyStocks
Which penny stocks are you buying right now?
The post These Penny Stocks Climbed Today, Here’s Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
These Penny Stocks Climbed Today, Here's Why
12:37pm, Thursday, 16'th Dec 2021
Which penny stocks are you buying right now? The post These Penny Stocks Climbed Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Dare's (DARE) Xaciato Gets FDA Nod for Bacterial Vaginosis
03:33pm, Thursday, 09'th Dec 2021 Zacks Investment Research
Dare (DARE) gets FDA approval for Xaciato (clindamycin phosphate) vaginal gel as a treatment for bacterial vaginosis.
Dare's (DARE) Xaciato Gets FDA Nod for Bacterial Vaginosis
12:18pm, Thursday, 09'th Dec 2021
Dare (DARE) gets FDA approval for Xaciato (clindamycin phosphate) vaginal gel as a treatment for bacterial vaginosis.
BZ Chart Of The Day: Dare Bioscience
03:50pm, Wednesday, 08'th Dec 2021 Benzinga
If markets have memories, shares of Daré Bioscience, Inc. (NASDAQ: DARE) may be in trouble. The stock has run into a resistance level.
Resistance is a large group of sellers offering their shares at
Dare Bioscience Stock (DARE): Why The Price Surged
12:49am, Wednesday, 08'th Dec 2021
The stock price of Daré Bioscience Inc (NASDAQ: DARE) increased by 10.52% in the most recent trading session. This is why it happened.
Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis
09:15pm, Tuesday, 07'th Dec 2021 GlobeNewswire Inc.
SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) approve
Daré Bioscience's One-Time Bacterial Vaginosis Treatment Scores FDA Approval
06:07pm, Tuesday, 07'th Dec 2021 Benzinga
The FDA has approved Daré Bioscience Inc (NASDAQ: DARE) Xaciato (DARE-BV1) to treat bacterial vaginosis.
Xaciato is a thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% desig
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
01:17pm, Tuesday, 07'th Dec 2021 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome
Acadia Pharmaceuticals Inc. (N
Daré Bioscience's One-Time Bacterial Vaginosis Treatment Scores FDA Approval
01:07pm, Tuesday, 07'th Dec 2021
The FDA has approved Daré Bioscience Inc (NASDAQ: DARE) Xaciato (DARE-BV1) to treat bacterial vaginosis. Xaciato is a thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% desig
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
11:07am, Monday, 06'th Dec 2021 Benzinga
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r
Dare Bioscience Stock (DARE): Why The Price Increased Today
06:48am, Monday, 06'th Dec 2021
The stock price of Daré Bioscience Inc (NASDAQ: DARE) increased by over 3% pre-market today. This is why it happened.
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
05:02pm, Thursday, 02'nd Dec 2021 Benzinga
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for the year-to-date peri
